NFJ Investment Group LLC Acquires 6,282 Shares of IQVIA Holdings Inc. (NYSE:IQV)

NFJ Investment Group LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 20.5% during the 4th quarter, Holdings Channel reports. The fund owned 36,893 shares of the medical research company’s stock after buying an additional 6,282 shares during the period. NFJ Investment Group LLC’s holdings in IQVIA were worth $7,250,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Synergy Asset Management LLC purchased a new position in IQVIA during the fourth quarter valued at $33,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $44,000. Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. bought a new stake in IQVIA during the 4th quarter worth approximately $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Truist Financial dropped their price target on shares of IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research report on Thursday, April 10th. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Robert W. Baird lowered their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Barclays reiterated an “equal weight” rating and set a $170.00 target price (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Stock Performance

NYSE IQV opened at $148.73 on Thursday. The business’s 50 day moving average price is $178.83 and its 200-day moving average price is $198.11. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a market cap of $26.22 billion, a P/E ratio of 19.83, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.